The present disclosure relates to a novel humanized antibody capable of binding to ADAM17 and also the amino and nucleic acid sequences coding for said antibody. From one aspect, the disclosure relates to a novel humanized antibody, or antigen-binding fragments, capable of binding to ADAM17 with anti-tumour activities. The disclosure also comprises the use of said humanized antibody as a drug for the treatment of cancer. Finally, the invention comprises compositions comprising said humanized antibody, alone or in combination or conjugation with other anticancer compounds, and the use of same for the treatment of cancer.
